—Maybe, say the results of a UK meta-analysis, which found some patients to benefit from the alternative approach. Considering the side effects of certain OAB medications and poor adherence, it’s ...

Standard stepwise therapy for overactive bladder (OAB) begins with conservative therapies such as lifestyle interventions and behavioral approaches. Medications—anticholinergics or beta-3 agonists—are ...

OAB is commonly treated with a class of medicines called anticholinergics or antimuscarinics. These medicines block chemicals in your body that help the bladder to squeeze. By blocking these chemicals ...

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending vibegron (Obgemsa, Pierre Fabre) for treating overactive bladder (OAB) syndrome in adults. The ...

Paris, Jan. 06, 2026 (GLOBE NEWSWIRE) -- 88% reduction in urinary incontinence episodes in patients with neurogenic bladder sustained through ...

(Reuters) - The popular Botox wrinkle treatment made by Allergan Inc has been approved to treat adults with overactive bladder who cannot tolerate or failed to be helped by other drugs for the ...

Women with overactive bladder are frequently frustrated with treatment, which leads to discontinuation of therapy. Asynchronous telehealth visits keep women engaged in follow-up care, accelerates ...

Do you often feel a sudden, intense urge to urinate that disrupts your daily life? If so, you may be experiencing one of the most common overactive bladder symptoms. Understanding the signs to look ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The novel muscarinic M3 receptor antagonist DA8010 ...

Active ingredient: Fesoterodine fumarate 4 mg, 8 mg; extended-release tablets. Indication: Overactive bladder (OAB) with urge urinary incontinence, urgency, and frequency. Pharmacology: Fesoterodine ...

The "Overactive Bladder Treatment Market by Pharmacotherapy and Disease Type - Global Forecast to 2022" report has been added to Research and Markets' offering. The global overactive bladder treatment ...